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A B S T R A C T
Background: The use of sum scores of depressive symptoms has been increasingly criticized and may be parti-
cularly problematic in oncological settings. Frameworks analyzing individual symptoms and their inter-
relationships such as network analysis represent an emerging alternative.
Methods: We aimed to assess frequencies and interrelationships of 9 DSM-5 symptom criteria of major depres-
sion reported in the PHQ-9 questionnaire by 4020 patients with cancer and 4020 controls from the general
population. We estimated unregularized Gaussian graphical models for both samples and compared network
structures as well as predictability and centrality of individual symptoms.
Results: Depressive symptoms were more frequent, but less strongly intercorrelated in patients with cancer than
in the general population. The overall network structure differed significantly between samples (correlation of
adjacency matrices: rho=0.73, largest between-group difference in any edge weight: 0.20, p < 0.0001). Post-
hoc tests showed significant differences in interrelationships for four symptom pairs. The mean variance of
symptoms explained by all other symptoms in the same network was lower among cancer patients than in the
general population (29% vs. 43%).
Limitations: Cross-sectional data do not allow for temporal or causal inferences about the directions of asso-
ciations and results from population-based samples may not apply to clinical psychiatric populations.
Conclusions: In patients with cancer, both somatic and cognitive/affective depression symptoms are less likely to
be explained by other depressive symptoms than in the general population. Rather than assuming a consistent
depression construct, future research should study individual depressive symptom patterns and their potential
causes in patients with cancer.
1. Introduction
The level of depression, assessed by the sum score of a standardized
self-report questionnaire, is among the most frequently reported psy-
chological outcomes in the context of cancer care. Recent findings have
however questioned the common practice to operationalize depression
severity as the sum score of depressive symptoms. Two patients who
have the same sum score on a depression questionnaire may not share a
single symptom, due to the heterogeneity of symptom patterns (Fried
and Nesse, 2015; Olbert et al., 2014). Using a single sum score of a
depression measure further presumes that it is unidimensional, i.e. that
all symptoms are roughly interchangeable measures of depression. A
substantial body of psychometric research has, however, demonstrated
that many common depression measures are multidimensional (Fried
et al., 2016; Shafer, 2006). This means that, statistically, two or more
scores better reflect how the measured depressive symptoms are in-
tercorrelated with each other.
Using the sum score of depressive symptoms may be particularly
problematic in oncological populations. The prevalence of depression in
cancer tends to be much higher when assessed by sum scores and their
cut-offs compared to standardized diagnostic interviews (Hartung et al.,
2017a; Mehnert et al., 2014; Mitchell et al., 2011; Vehling et al., 2012).
In addition, there is a large diagnostic discrepancy between the Patient
Health Questionnaire-9 (PHQ-9), an established self-report depression
questionnaire, and the standardized CIDI interview (Hartung et al.,
2017b; Mehnert et al., 2014). Interestingly, this discrepancy was larger
in cancer patients than in general medical patients across all possible
cutoff values of the PHQ-9 (Hartung et al., 2017b; Löwe et al., 2004b).
While algorithms which prioritize some items over others may achieve
better accuracy than sum scores weighting all items equally (Lie et al.,
https://doi.org/10.1016/j.jad.2019.06.009
Received 2 March 2019; Received in revised form 20 April 2019; Accepted 3 June 2019
⁎ Corresponding author.
E-mail address: tim.hartung@medizin.uni-leipzig.de (T.J. Hartung).
Journal of Affective Disorders 256 (2019) 295–301
Available online 04 June 2019
0165-0327/ © 2019 Elsevier B.V. All rights reserved.
T
2015), there is evidence that even the best-established algorithms show
a low diagnostic accuracy compared to a standardized interview in
oncological settings (Hartung et al., 2017b). In addition, there is evi-
dence for multidimensionality of frequently used depression ques-
tionnaires such as the Hospital Anxiety and Depression Scale (HADS) in
oncological samples, suggesting that the one-factor solution may be at
least as problematic in patients with cancer as in other patient popu-
lations (Hinz et al., 2016).
These recent findings contribute to a long-lasting debate about the
adequacy of standard diagnostic criteria of depression in patients with
cancer. Several approaches to exclude or replace depression criteria
confounded by medical illness such as fatigue, diminished appetite,
sleep disturbance, and diminished concentration have been proposed
(Trask, 2004; Zimmerman et al., 2006). Although evidence on this issue
is limited, studies suggest that patients with cancer report all depressive
symptoms significantly more often than the general population, with
particularly large differences in somatic symptoms (Hinz et al., 2016,
2010; Osborne et al., 2004). Consequently, excluding or substituting
somatic symptoms leads to substantially different prevalence estimates
of depression (Saracino et al., 2018; Sharpley et al., 2017). Yet, few
studies have investigated the interrelationship between somatic and
cognitive-emotional depressive symptoms in cancer (Jones et al., 2015;
Mitchell et al., 2012, Nikendei et al., 2018). These studies consistently
found no relevant differences in item functioning or diagnostic utility
between somatic and non-somatic depression symptoms. However,
none of the studies used a representative control group (either no non-
cancer control group at all or only psychiatric control patients with an
even higher depression severity than in the depressed patients with
cancer).
Thus, it is still unclear (1) to what extent patients with cancer differ
from the general population in terms of individual depressive symp-
toms, (2) how depressive symptoms are interrelated with each other
among patients with cancer, and (3) whether these interrelationships
among individual depressive symptoms differ from those in the general
population, which may be relevant to the diagnosis and treatment of
depression in patients with cancer.
One approach to address these questions is the symptomics frame-
work (Fried, 2017), which focuses on individual symptoms and their
(potentially causal) relationships among each other. Conceptually, this
framework understands individual depression symptoms as important
constructs in their own right (Persons, 1986)— concentration problems
are viewed as a different entity than suicidal ideation or sadness, rather
than as expressions of the same underlying process — and con-
ceptualizes depression as an emergent property that may arise due to
associations and vicious circles among symptoms. This theoretical fra-
mework can be statistically investigated via network psychometrics
(Epskamp, 2017). Estimated network models can be visualized: they
contain nodes (symptoms) and edges (relationships among pairs of
nodes), usually computed as partial correlations (Borsboom, 2017). To
our knowledge, this approach has not been applied to depressive
symptoms in patients with cancer so far.
Therefore, the aim of this study was to assess and compare fre-
quency and severity of individual depressive symptoms in patients with
cancer and the general population and to explore the interrelations
among these symptoms using network models. We estimated and
compared the overall network structure, predictability and centrality of
depressive symptoms across samples from two populations: patients
with cancer and the general population.
2. Methods
2.1. Participants and data collection
We analyzed data from two studies: The first is a representative
sample of 4020 patients with cancer with all major cancer types, re-
cruited in a cross-sectional, prospective, multicenter study in five
regions across Germany between 2007 and 2011 (Hartung et al., 2017a;
Mehnert et al., 2014, 2012). Patients were recruited from a total of 84
inpatient wards, outpatient clinics and cancer rehabilitation centers
during cancer treatment or follow-up, stratified by cancer type in pro-
portion to the nation-wide cancer incidence. Patients were asked to fill
in the questionnaires at their respective cancer treatment or re-
habilitation center.
The second sample was selected from two nationally representative
general population surveys conducted in Germany between 2003 and
2008 (n=2500 and n=2518) (Kocalevent et al., 2013). Here, ran-
domly selected participants were given questionnaires during home
visits. From the total sample (n=5018), 4020 controls were auto-
matically matched to patients first by sex and second by age (as closely
as possible) using the matchControls function from the R package e1071
(Meyer et al., 2017).
2.2. Measures
Sociodemographic data were collected with standardized ques-
tionnaires and medical data were collected from hospital charts.
Depressive symptoms were assessed with the German version of the
Patient Health Questionnaire 9-item Depression Module (PHQ-9),
which is a validated, reliable and widely used self-report measure with
an internal reliability of Cronbach's α=0.89 and a test-retest correla-
tion r=0.84 within 48 h in primary care patients (Kroenke et al., 2001;
Löwe et al., 2004a). Participants are asked to report the occurrence of
each of the 9 depressive symptom criteria in the DSM-IV during the past
two weeks as ‘0’ (not at all), ‘1’ (several days), ‘2’ (more than half the
days), or ‘3’ (nearly every day): (1) interest loss (“Little interest or
pleasure in doing things”), (2) depressed mood (“Feeling down, de-
pressed or hopeless”), (3) sleep (“Trouble falling asleep, staying asleep,
or sleeping too much”), (4) energy loss (“Feeling tired or having little
energy”), (5) appetite change (“Poor appetite or overeating”), (6)
worthlessness (“Feeling bad about yourself – or that you're a failure or
have let yourself or your family down”), (7) trouble concentrating
(“Trouble concentrating on things, such as reading the newspaper or
watching television”), (8) psychomotor issues (“Moving or speaking so
slowly that other people could have noticed. Or, the opposite – being so
fidgety or restless that you have been moving around a lot more than
usual”), (9) suicidality (“Thoughts that you would be better off dead or
of hurting yourself in some way”).
2.3. Statistical procedures
All statistical analyses were performed using R Version 3.3.1. All
tests were two-sided and p-values of multiple comparisons were
Holm–Bonferroni corrected.
To estimate the frequency (and 95% confidence interval) of each
symptom, symptom scores were dichotomized at the cutoff ≥2 (oc-
curring more than half the days during the past two weeks). Means
were compared using t-tests, frequencies using chi-squared tests.
Network structures of PHQ-9 items in each group were analyzed as
follows. Spearman's correlation matrices for each group were calcu-
lated. Based on these correlations, interrelationships between items
were estimated as partial correlations. As our dataset contained only
nine variables but thousands of observations, regularization was not
needed (Williams and Rast, 2018). Therefore, unregularized Gaussian
graphical models (GGM) were computed using the ggmModSelect func-
tion from the package qgraph (version 1.5)(Epskamp et al., 2012). The
function runs the graphical least absolute shrinkage and selection op-
erator (glasso) for 100 different tuning parameters to obtain 100 dif-
ferent network structures. It then chooses the best model according to
the Bayesian information criterion (BIC) and then tests all possible ways
to improve the BIC by adding or removing edges.
The predictability of each node was estimated using the package
mgm (Haslbeck and Fried, 2017). Predictability is defined as the
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variance in a node that is explained by all other nodes in the network.
The resulting network was analyzed using node strength centrality, an
index from graph theory (Epskamp et al., 2018; Opsahl et al., 2010).
The strength of a node is equal to the sum of all absolute associations,
e.g. partial correlations that this node exhibits with all other nodes.
The network models were graphed using the Fruchterman–Reingold
algorithm (“spring” layout from package qgraph), representing items as
nodes and partial correlation coefficients as lines between the nodes,
referred to as “edges”. In this layout, highly correlated nodes are placed
closer together, such that nodes with many strong correlations appear
near the center of the network and nodes with fewer and/or weaker
correlations are pushed to the periphery. To facilitate visual compar-
ison of the networks, the average layout across both samples is pre-
sented. Predictability was visualized as a ring-shaped pie chart around
the nodes, i.e. a completely filled ring would indicate that 100% of the
variance of the node is explained by its correlations with the other
symptoms of the network.
The structural similarity of the two networks was estimated using
the Spearman correlation of the two adjacency matrices, i.e. the ma-
trices of edge weights for each network (Fried et al., 2018; Rhemtulla
et al., 2016). To estimate differences in the relationships between de-
pressive symptoms in the two populations, we statistically compared
differences in network structures with the Network Comparison Test
(NCT) (van Borkulo et al., 2016). The NCT is a permutation test which
randomly splits the data set and refits the network models repeatedly
(1000 times in our analysis) to generate a reference distribution re-
presenting the null-hypothesis that there is no difference between the
networks estimated in the two observed groups (in our case, general
population vs. patients with cancer). The significance of group differ-
ences in three parameters can be tested in relation to the reference
distribution: (1) network structure, quantified as the maximum differ-
ence in any edge weight, (2) differences in individual edge weights, and
(3) difference of global network strength, defined as the sum of all node
strengths. To achieve results exactly matching the network models
above, the NCT was performed with a modified version of the package
NetworkComparisonTest (Jones, 2018) which allowed for unregularized
networks of Spearman correlations.
2.4. Sensitivity analyses
Unregularized model search for GGM is a relatively new approach
especially suited for data like ours with few variables and many ob-
servations. As this is less established than regularized model search
algorithms, we evaluated potential differences between the adjacency
matrices (i.e., the edge weights) resulting from unregularized and
regularized network models by Spearman correlations. We further
compared the adjacency matrices resulting from unregularized and
neighborhood regression network models (which were the basis for
predictability estimates). As suggested by one of the reviewers, we
performed subgroup analyses for patients in curative and palliative
cancer treatment.
2.5. Ethics and transparency
The original studies were conducted in accordance with the Helsinki
Declaration of 1975, as revised in 2008. All participants provided
written informed consent and data protection was secured in ac-
cordance with German data protection laws (§§27-30a BDSG;
Kocalevent et al., 2013; Mehnert et al., 2012). The patients study was
approved by ethics committees in all federal states involved (Mehnert
et al., 2012). R-code and correlation matrices are provided as Supple-
mentary materials online (www.osf.io/px9gk).
3. Results
3.1. Participants
Detailed sample characteristics were published previously for both
the general population sample (Kocalevent et al., 2013) and patients
with cancer (Hartung et al., 2017a) but are briefly summarized as fol-
lows: There were 51% women in both samples. Mean age was 55 years
(SD = 15 years) in the general population sample and 58 years
(SD = 11 years) in patients with cancer. In patients with cancer, the
mean time since diagnosis was 14 months (SD = 25 months). The most
frequent tumor locations were breast (n=906), prostate (n=637),
colorectal (n=510), female genital organs (n=317) and hematolo-
gical (n=305).
3.2. Item scores and correlations
All PHQ-9 items showed significantly higher mean values in patients
with cancer than in the general population (Table 1). Item standard
deviations were larger in patients with cancer and distribution of values
was more skewed towards lower values in the general population
(Table 1 and Supplementary material S1). When dichotomizing PHQ-9
items, all depressive symptoms (p < 0.001) except suicidality
(p > 0.243) were significantly more common in patients with cancer
than in the general population (Fig. 1). In both groups, the two most
common symptoms were sleep and energy loss, while suicidality was
the least common symptom.
All symptoms showed significant correlations with all other symp-
toms with medium Spearman correlations in the general population
(median r=0.41) and somewhat smaller correlations in patients with
cancer (median r=0.31; Supplementary material S2).
3.3. Network models
Partial correlation networks for both groups are shown in Fig. 2. In
Table 1
Descriptive item statistics and group differences.
General population Patients with cancer Hedges' g
M SD Pred Strengtha M SD Pred Strengtha
1 Interest loss 0.48 0.62 41% −0.72 0.85 0.89 33% 0.36 0.48⁎⁎⁎
2 Depressed mood 0.34 0.59 52% 1.83 0.67 0.75 39% 1.41 0.49⁎⁎⁎
3 Sleep 0.56 0.72 40% −0.67 1.35 1.08 25% −0.66 0.86⁎⁎⁎
4 Energy loss 0.60 0.69 50% 1.11 1.21 0.96 42% 1.74 0.73⁎⁎⁎
5 Appetite change 0.26 0.55 38% −0.44 0.80 1.01 27% −0.56 0.66⁎⁎⁎
6 Worthlessness 0.19 0.48 45% 0.48 0.27 0.60 24% −0.58 0.14⁎⁎⁎
7 Trouble concentrating 0.34 0.58 42% −0.14 0.70 0.84 29% 0.07 0.50⁎⁎⁎
8 Psychomotor issues 0.14 0.43 40% −0.02 0.43 0.77 21% −0.60 0.47⁎⁎⁎
9 Suicidality 0.09 0.34 39% −1.42 0.17 0.44 22% −1.17 0.20⁎⁎⁎
Abbreviations: M, mean; SD, standard deviation; Pred, predictability (proportion of the variance explained by all other symptoms in the network).
a Standardized node strength centrality (sum of edge weights connected with the node).
⁎⁎⁎ p < 0.001 after Holm–Bonferroni correction.
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both groups, 27 out of all possible 36 edges (75%) had an absolute
weight above zero. In the general population, the strongest edges were
sleep—energy loss, interest loss—depressed mood, psychomotor is-
sues—suicidality; in patients with cancer, the strongest edges were in-
terest loss—depressed mood, energy loss—appetite change and slee-
p—energy loss (Supplementary material S3). The predictability of
symptoms, i.e. the percentage of a node's variance explained by all
other symptoms in the network, is shown as ring-shaped pie charts in
Fig. 2. Mean predictability was 43% in the general population and 29%
in patients with cancer. Depressed mood (52%), energy loss (50%) and
worthlessness (45%) had the highest predictability in the general po-
pulation, while energy loss (42%), depressed mood (40%), and interest
loss (33%) had the highest predictability in patients with cancer.
Standardized node strength centrality differed substantially for in-
terest loss and worthlessness (Fig. 3).
3.4. Comparison of networks
While considerable similarities between adjacency matrices
(Spearman's rho = 0.73) and node strength centralities (rho = 0.79)
emerged, the NCT revealed significant differences between the two
networks on a structural level: the maximum difference in any edge
weight was 0.20 (p < 0.0001), indicating significantly different overall
structure. Post-hoc tests showed that four out of 36 edges (11%) had
significantly different weights in the two networks (all p < 0.0001):
energy loss—appetite change, depressed mood—suicidality, energy
loss—suicidality and psychomotor issues—suicidality (Fig. 2). In addi-
tion, global strength differed significantly between the two networks
(general population: 3.80, patients with cancer: 3.47, p < 0.0001),
which means that the general population network was more densely
connected. This is in alignment with the larger average predictability
values in the general population network.
3.5. Sensitivity analyses
Overall, our particular modeling choice (unregularized GGM model
selection using Spearman correlations) did not have an impact on the
obtained results; results were essentially unchanged using neighbor-
hood regression (all absolute differences in edge weights ≤ 0.05;
Spearman correlation of adjacency matrices rho: 0.95 and 0.97;
Supplementary Material S4) and regularized approach (all absolute
differences in edge weights ≤ 0.04; Spearman correlation of adjacency
matrices rho: 0.99 and 0.98; Supplementary Material S5). This speaks to
the robustness of both our results and the different network estimation
routines. Subgroup analyses showed that all symptoms except worth-
lessness and trouble concentrating were significantly more severe in
patients in palliative compared to curative cancer treatment while there
were no substantial differences in interrelationships and network


































Fig. 1. Relative frequency and 95% confidence intervals of PHQ-9 depressive symptoms in patients with cancer (CA) and controls from the general population (GP).





















Fig. 2. Partial correlation networks of PHQ-9 depressive symptoms in patients
with cancer and controls from the general population. Ring-shaped pie charts
represent predictability (a fully filled dark ring would indicate that 100% of the
symptom's variance is explained by its intercorrelations with the other symp-
toms in the network), edges that differ significantly in size across networks are
shown in black (see Supplement Table S3 for edge weights and their difference).
Legend: 1 Interest loss, 2 Depressed mood, 3 Sleep, 4 Energy loss, 5 Appetite
change, 6 Worthlessness, 7 Trouble concentrating, 8 Psychomotor issues, 9
Suicidality.




This is the first study to compare network structures of depressive
symptoms in patients with cancer and the general population.
Depressive symptoms showed a significantly lower global connectivity
in patients with cancer compared to the general population. This sug-
gests that symptoms tend to depend less on other symptoms in the
network in cancer patients. Consistent with this finding, all symptoms
showed lower predictability (proportion of variance explained by all
other symptoms in the network) in individuals with cancer than in the
general population. One interpretation of this finding is that, in cancer
populations, a larger proportion of the variance of depressive symptoms
is explained by external variables which do not appear in the network.
Such variables may include tumor- and treatment-related factors such
as pain, neurological deficits, chemotherapy or hormone therapy
(Jones et al., 2015).
4.2. Frequency of depressive symptoms
All depressive symptoms were reported more frequently in patients
with cancer than in the general population sample, which is consistent
with previous studies (Hinz et al., 2016, 2010; Osborne et al., 2004).
This difference was particularly large for somatic symptoms such as
sleep problems, energy loss and appetite change, which may directly or
indirectly be caused by cancer and its treatment.
4.3. Symptom-level group differences
Four items showed substantial differences between the two groups:
sleep, worthlessness, interest loss, and suicidal ideation. Sleep dis-
turbances were significantly more common in patients with cancer than
in the general population, showing the largest standardized difference
in mean scores between groups (Hedges’ g=0.86). While this symptom
also had a substantially lower predictability in patients with cancer
(25% vs. 40% in the general population), there was no difference in
relative node strength centrality and none of the edges connected to this
node differed significantly between groups. This suggests that sleep
disturbances may be substantially more frequent due to factors other
than depressive symptoms, while still bearing a similar relationship to
other depressive symptoms and/or their causes as in the general po-
pulation.
Worthlessness (“feeling bad about oneself”) showed the largest
difference in predictability between groups (45% in the general popu-
lation vs. 24% in patients with cancer). This symptom was much less
predictable and, at the same time, much less central among cancer
patients. One possible explanation for this interesting structural dif-
ference between the networks with regard to a sense of worthlessness
may lie in the psychological underpinnings of cancer-related stressors.
Depression theories discuss that a bias to blame oneself for failure in an
overgeneralized way may underlie this symptom pathophysiologically
(Zahn et al., 2015). These mechanisms may however be much less re-
levant for individuals with cancer, who are frequently confronted with
dignity- and self-worth-threatening situations (changes in appearance,
loss of functioning, dependency). Thus, we speculate that in some cases
a sense of worthlessness may be more strongly associated with such
external cancer-related factors than with negative cognitive biases in
patients with cancer.
Centrality measures such as node strength centrality may guide the
search for symptoms that activate or maintain psychopathology net-
works. Energy loss was the most central symptom in patients with
cancer (standardized node strength centrality 1.74). Longitudinal stu-
dies are needed to assess whether this symptom precedes associated
symptoms or whether it represents their common end points. If the
former is the case, patients’ energy levels may improve a whole range of
depressive symptoms. Anhedonia or loss of interest was substantially
more central in patients with cancer than in the general population,
showing the largest positive group difference in relative node strength
(standardized node strength centrality 0.36 vs. −0.72 respectively).
Future research could assess whether special attention to this symptom
may improve diagnostics and therapy in oncological populations.
Suicidal ideation had the largest number of significantly different
edges between groups, while it was similarly central in both networks.
This suggests that this symptom plays a similar role in the overall
network, while being associated with different symptoms within the
network. Among patients with cancer, suicidal ideation, especially in
the more passive form of thoughts about death, can have different
meanings. On the one hand, it could be part of a state of severe despair,
which would explain the strong link to lowered mood in the network
(Nissim et al., 2009); but it could, among patients with terminal cancer,
also indicate a feeling of acceptance and letting go, which may explain
the residual association with loss of energy in cancer, which did not
emerge in the general population. For another subgroup of patients,
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Fig. 3. Standardized node strength centrality for PHQ-9 depressive symptoms
in patients with cancer (CA) and the general population (GP).
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self-confronting coping with their life-threatening disease. The differ-
ential relationships in the cancer network thus underline the com-
plexity of this symptom in cancer.
The role of suicidality within the network of depressive symptoms
may also differ between patients with early and those with advanced
disease. When facing a life‐threatening disease, suicidality may de-
crease as the threat of one's life is already located in the (exterior)
disease and thus diminishes the (internal) desire to end one's life.1
However, our subgroup analyses showed that suicidal thoughts were
significantly more severe in patients in palliative treatment compared
to patients in curative treatment and we found no substantial differ-
ences in network structures between the two groups.
4.4. Implications for diagnostics and treatment in oncological settings
The low cohesion and within-network predictability of depressive
symptoms in patients with cancer are consistent with the idea that
many depressive symptoms may be caused by factors outside the
symptom network. Some of these factors may be related to cancer and
its treatment. Such causal hypotheses can be formulated not only for
somatic symptoms, but also for cognitive and affective symptoms, as
discussed above. While somatic symptoms of depression may be parti-
cularly common in patients with cancer, these symptoms did not stand
out in terms of their interrelationships with other depression symptoms.
Our results underline the heterogeneity of depressive symptom patterns
and the complex roles that individual symptoms may play in patients’
overall psychosocial symptom burden.
Although depression symptoms are very frequent in cancer, health
care professionals often feel badly equipped to manage them
(Kissane, 2014). In this regard, our results tie in with an increasing
acknowledgement in the literature that the concept of depression as a
psychiatric category may be of limited use for clinical management of
depression symptoms in the cancer context (King, 2017). Our results
add further insights into this observed mismatch. While a sum score of
depressive symptoms can serve as an indicator of psychosocial
symptom burden, clinicians should assess symptoms individually and
consider potential causes and solutions for each symptom in a patient-
centered approach. This may occur in a psychotherapeutic context, but
can also guide oncological treatment decisions and side-effect man-
agement, as well as inform pharmacological treatment choices.
4.5. Strengths and limitations
Strengths of our study include the large, representative population-
based samples; highly accurately estimated parameters in the network
models; and sensitivity analyses demonstrating that the particular
choice of network model did not affect the results.
Our results ought to be interpreted in light of the following lim-
itations: First, the data we analyzed stemmed from cross-sectional
studies, which do not allow temporal or causal inferences about the
directions of the observed associations. Second, we analyzed popula-
tion-based samples, in which most of the participants did not fulfill the
criteria of a mental disorder; results can thus not be generalized to
clinical psychiatric populations. Third, while the PHQ-9 is a psycho-
metrically strong instrument adhering to the DSM-5 criteria of major
depression, it does not deliver the same level of detail as longer ques-
tionnaires and partially achieves its brevity by combining two direc-
tions of a symptom in a single bidirectional item (e.g. appetite loss or
gain). Future studies could obtain more fine-grained results by using
longer scales which distinguish between all possible directions of
symptoms.
4.6. Conclusion
Although depressive symptoms are much more frequent in in-
dividuals with cancer, they are less cohesively related to each other.
Depression symptoms are more likely to be associated with non-
symptom factors in patients with cancer than in the general population.
Notably, the present results indicate that this pattern does not only
apply to somatic, but also to cognitive and affective depressive symp-
toms. The significant structural differences between the networks fur-
ther strengthen the need to better understand what lies behind de-
pressive symptoms in cancer. A more detailed inquiry into the pathways
from disease and treatment-related factors to such symptoms can in-
form psychosocial interventions to aim beyond “alleviating depres-
sion”. Rather than assuming a consistent depression construct, in-
dividual depressive symptom patterns and their potential causes should
be considered in individuals with cancer.
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